spacer
home > epc > spring 2009 > beyond technology
PUBLICATIONS
European Pharmaceutical Contractor

Beyond Technology

As electronic data capture (EDC) is becoming the standard for clinical trials, CROs are under pressure to offer this system and carry out projects that competitively meet time, cost and quality demands. Decisions about the choice of EDC partner must take the sponsor’s interests into account in order to establish an efficient collaboration. EDC vendors are advised to offer special programmes for this purpose.

STRATEGIC EDC PARTNERSHIPS

According to Thomson CenterWatch, the proportion of EDC studies in 2007 exceeded the 40 per cent mark for the first time, with respect to all clinical studies commissioned worldwide (1). Furthermore, it is predicted that this technology will become the standard by 2010. Since further prognoses indicate that the market tends towards standardisation of EDC systems, many CROs choose not to develop their own system and instead work together with specialised EDC vendors.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer

Claudia Horneck is the Director PR/Promotion of clinIT AG, but also works as a selfemployed Consultant working closely with pharmaceutical contract research organisations. She received her Masters in German Literature, Linguistics and Philosophy from the Albert-Ludwigs University, Freiburg, Germany. Prior to her position at clinIT AG, Claudia held the positions of Head of Sales Administration and Customer Relations Manager at Thomae & Partner AG, Freiburg.

spacer
Claudia Horneck
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Prince Helps Sustainable Pharma Packaging Pioneers Woolcool Celebrate 10th Anniversary

Ground-breaking sustainable pharma packaging firm Woolcool celebrated a decade of innovation with a visit by HRH The Prince of Wales.
More info >>

White Papers

The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation

BioPharmaSpec

1. Introduction As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India forhigh quality, low   cost pharma solutions, CPhI & P-MEC Indiais the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India’s pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement